SCHEMBL4087849

SCHEMBL4087849

Brc1ccccc1[C](c1ccccc1Br)c1ccccc1Br

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ELANE P08246 1/20 0.41
HPGD P15428 3/20 0.40
POLB P06746 2/20 0.40
HTT P42858 1/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14742464 0.84 MEN1 (0.48) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL153460 0.79 NPC1 (0.42) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL8497069 0.77 NPC1 (0.41) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL5172196 0.77 ALDH1A1 (0.43) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL29470997 0.77 PRNP (0.53) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL1681866 0.77 PRNP (0.53) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL1802165 0.77 CES2 (0.50) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL409564 0.75 HPGD (0.48) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL3844423 0.75 PRNP (0.57) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL15632883 0.75 L3MBTL1 (0.45) NPC1RAB9AALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9233922-B2 Process for producing N-(hetero)arylazoles TAKASAGO INTERNATIONAL CORPORATION (JP) 2016-01-12 US disclosed
EP-2736881-B1 PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES TAKASAGO PERFUMERY CO LTD (JP) 2015-10-07 EP disclosed
US-20140371461-A1 PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-12-18 US disclosed
EP-2736881-A1 PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES Takasago International Corporation (JP) 2014-06-04 EP disclosed
WO-2013032035-A1 PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-03-07 WO disclosed
EP-2048168-A2 Process for producing catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048170-A2 Second catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048167-A2 First catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
EP-2048169-A2 Third catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer Sumitomo Chemical Company, Limited (JP) 2009-04-15 EP disclosed
US-6914108-B2 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-07-05 US disclosed
US-20030203810-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2003-10-30 US disclosed
US-6586356-B2 Coordination catalyst SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-07-01 US disclosed
US-20010020075-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-06 US disclosed
EP-1113026-A2 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371461-A1 PROCESS FOR PRODUCING N-(HETERO)ARYLAZOLES CYP3A4, HCN4, PPOX NPC1 3396/4885RAB9A 4035/4885ALDH1A1 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.